Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Direvo Biotech has entered into an agreement with Evotec under which Evotec will transfer certain patents to Direvo that are currently licensed by Direvo.
Subscribe to our email newsletter
The patents protect key components of Direvo’s protein/strain engineering platform. Using this platform, Direvo develops products both independently and with global leaders such as AstraZeneca/MedImmune and Pfizer, as well as Danisco/Genencor and Nestle.
Thomas von Ruden, CEO of Direvo, said: “This is a very important milestone for the company, because Direvo now owns essential parts of intellectual property protecting its technology. This will give us much greater flexibility in the company’s future corporate development. It will allow us to spin out legal entities able to focus and further develop and customize the technology in their own markets.”